menu search

Biogen and eisai strengthen lead in alzheimer's drug race. the stocks are rising.

Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab....

November 30, 2022, 5:11 am

: a new alzheimer’s treatment may help some patients, though researchers say more safety data is needed

A new study found that Eisai and Biogen’s experimental alzheimer’s drug moderately reduced cognitiv...

November 30, 2022, 1:29 am

Biopharma co. trades to new 52-week high

Source: Streetwise Reports (11/28/22) Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successful...

November 29, 2022, 9:23 pm

Why this new alzheimer's update is likely to spark a debate for biogen investors

Biogen stock was muted late Tuesday after Eisai unveiled alzheimer's treatment results likely to spark ...

November 29, 2022, 8:44 pm

New alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementia

Doctors have hailed a "new era" of medicine after a study showed for the first time that a drug can slow the debilitating symptoms of ...

November 29, 2022, 8:09 pm

Eisai, biogen alzheimer's drug slows cognitive decline, safety for some becomes focus

New data was presented on Tuesday....

November 29, 2022, 7:55 pm

Alector presents results from first-in-human phase 1 study of al101 for the treatment of neurodegenerative diseases

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as ...

November 29, 2022, 4:05 pm

Biogen (biib) down on report of death in alzheimer's study

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its ...

November 29, 2022, 2:18 pm

Axsome (axsm) gains as alzheimer's agitation study meets goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating alzheimer's disease agitation met...

November 29, 2022, 2:18 pm

Why is axsome therapeutics (axsm) stock up 32% today?

Axsome Therapeutics (NASDAQ: AXSM ) stock is soaring higher on Monday after releasing positive results from a Phase 3 clinical trial. That Phase 3 cli...

November 28, 2022, 12:35 pm

Axsome therapeutics announces axs-05 achieves primary endpoint in the accord phase 3 trial in alzheimer’s disease agitation

AXS-05 statistically significantly delayed time to relapse of alzheimer’s disease agitation versus pl...

November 28, 2022, 11:35 am

Biogen dives on reports of alzheimer's death while axsome soars on its study success

Biogen stock toppled Monday after a report suggested its experimental alzheimer's treatment caused a pa...

November 28, 2022, 9:07 am

Axsome's stock rallies 15% on promising findings for its experimental alzheimer's drug

Shares of Axsome Therapeutics Inc. AXSM, +1.07% jumped 15.5% in premarket trading on Monday after the company said its ...

November 28, 2022, 8:36 am

Ac immune to present progress of alzheimer's disease programs targeting abeta and tau at the 15th ctad conference

Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine ...

November 23, 2022, 7:30 am

Inmune bio, high risk, higher reward.

The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities...

November 21, 2022, 12:45 pm

Athira pharma to present additional biomarker data from act-ad phase 2 study of fosgonimeton at the 2022 clinical trials on alzheimer's disease (ctad) conference

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurod...

November 21, 2022, 7:00 am

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm


Search within

Pages Search Results: